Imperial College London
Portrait Picture

MrMikaelSodergren

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Hepatopancreatobiliary Surgery
 
 
 
//

Contact

 

m.sodergren

 
 
//

Location

 

BN2/13Block B Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Troup:2022:10.3390/ijerph19127499,
author = {Troup, LJ and Erridge, S and Ciesluk, B and Sodergren, MH},
doi = {10.3390/ijerph19127499},
journal = {International Journal of Environmental Research and Public Health},
pages = {1--7},
title = {Perceived stigma of patients undergoing treatment with cannabis-based medicinal products},
url = {http://dx.doi.org/10.3390/ijerph19127499},
volume = {19},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Cannabis-based medicinal products (CBMPs) are prescribed with increasing frequency. This study aimed to investigate the perceived stigma attached to patients prescribed CBMPs in the UK to establish its prevalence. A qualitative survey was developed by an expert multidisciplinary group and data were collected via Qualtrics. In total, 2319 patients on CBMP therapy were invited to take part in this study. 450 (19.4%) participants completed the questionnaire. In total, 81.3% (n = 366), 76.9% (n = 346), and 61.3% (n = 276) of participants reported feeling very comfortable or comfortable telling friends, family, and medical professionals, respectively, about their treatment. Participants thought that friends (n = 372; 82.7%) and family (n = 339; 75.3%) were very approving or somewhat approving of their CBMP prescription. However, participants thought that only 37.8% (n = 170) of healthcare professionals and 32.9% (n = 148) of society in general were very approving or somewhat approving of their CBMP prescription. 57.1% (n = 257), 55.3% (n = 249), and 40.2% (n = 181) of participants were afraid of what the police or criminal justice system, other government agencies, and healthcare professionals might think about their treatment. This study highlights those patients treated with CBMPs experience a high prevalence of perceived stigma from many corners of society. Future work should be undertaken to explore strategies to reduce perceived stigma at an individual and community level to avoid discrimination of patients, likely increasing appropriate access.
AU  - Troup,LJ
AU  - Erridge,S
AU  - Ciesluk,B
AU  - Sodergren,MH
DO  - 10.3390/ijerph19127499
EP  - 7
PY  - 2022///
SN  - 1660-4601
SP  - 1
TI  - Perceived stigma of patients undergoing treatment with cannabis-based medicinal products
T2  - International Journal of Environmental Research and Public Health
UR  - http://dx.doi.org/10.3390/ijerph19127499
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000816203300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://mdpi.com/1660-4601/19/12/7499
UR  - http://hdl.handle.net/10044/1/100573
VL  - 19
ER  -
Download